First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)

European Journal of Cancer ◽

10.1016/j.ejca.2017.04.024 ◽

2017 ◽

Vol 81 ◽

pp. 191-202 ◽

Author(s):

Alfredo Carrato ◽

Albert Abad ◽

Bartomeu Massuti ◽

Cristina Grávalos ◽

Pilar Escudero ◽

...

Keyword(s):

Colorectal Cancer ◽

Liver Metastases ◽

Phase Ii ◽

Phase Ii Trial ◽

Unresectable Liver Metastases

Download Full-text

Modified FOLFOXIRI With or Without Cetuximab as Conversion Therapy in Patients with RAS / BRAF Wild‐Type Unresectable Liver Metastases Colorectal Cancer: The FOCULM Multicenter Phase II Trial

The Oncologist ◽

10.1634/theoncologist.2020-0563 ◽

2020 ◽

Author(s):

Huabin Hu ◽

Kun Wang ◽

Meijin Huang ◽

Liang Kang ◽

Wei Wang ◽

...

Keyword(s):

Colorectal Cancer ◽

Liver Metastases ◽

Phase Ii ◽

Phase Ii Trial ◽

Wild Type ◽

Conversion Therapy ◽

Multicenter Phase ◽

Unresectable Liver Metastases

Download Full-text

Safety and Efficacy of Intravenous Cetuximab (CET) and Hepatic Artery Infusion of Irinotecan, 5-Fluorouracil and Oxaliplatin in Patients with Unresectable Liver Metastases from Wt Kras Colorectal Cancer (CRC): Results from Optiliv European Phase II Trial

Annals of Oncology ◽

10.1016/s0923-7534(20)33179-3 ◽

2012 ◽

Vol 23 ◽

pp. ix194

Author(s):

F. Levi ◽

V. Boige ◽

P. Rougier ◽

M. Hebbar ◽

D. Smith ◽

...

Keyword(s):

Colorectal Cancer ◽

Liver Metastases ◽

Hepatic Artery ◽

Phase Ii ◽

Phase Ii Trial ◽

Hepatic Artery Infusion ◽

Safety And Efficacy ◽

Unresectable Liver Metastases

Download Full-text

Percutaneous hepatic perfusion with melphalan in treating unresectable liver metastases of colorectal cancer and uveal melanoma: A phase ii trial

HPB ◽

10.1016/j.hpb.2016.01.194 ◽

2016 ◽

Vol 18 ◽

pp. e734

Author(s):

E.M. de Leede ◽

M.C. Burgmans ◽

C.H. Martini ◽

J. Vuyk ◽

F.G.J. Tyl ◽

...

Keyword(s):

Colorectal Cancer ◽

Liver Metastases ◽

Uveal Melanoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Hepatic Perfusion ◽

Unresectable Liver Metastases ◽

Percutaneous Hepatic Perfusion

Download Full-text

Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) after chemotherapy (CT) with CPT-11/L-OHP/LV5FU (Folfirinox): A prospective phase II trial

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.3613 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3613-3613 ◽

Author(s):

F. Quenet ◽

B. Nordlinger ◽

M. Rivoire ◽

J. R. Delpero ◽

G. Portier ◽

...

Keyword(s):

Colorectal Cancer ◽

Liver Metastases ◽

Phase Ii ◽

Phase Ii Trial ◽

Prospective Phase ◽

Unresectable Liver Metastases

Download Full-text

Safety and efficacy of neoadjuvant combination of hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil, and oxaliplatin with intravenous (iv) cetuximab in patients with unresectable liver metastases from colorectal cancer (CRC): Interim report from OPTILIV—A European multicenter phase II trial.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.e14102 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. e14102-e14102

Author(s):

M. Ducreux ◽

P. Rougier ◽

D. Smith ◽

C. N. J. Focan ◽

P. F. Innominato ◽

...

Keyword(s):

Colorectal Cancer ◽

Liver Metastases ◽

Hepatic Artery ◽

Phase Ii ◽

Phase Ii Trial ◽

Hepatic Artery Infusion ◽

Interim Report ◽

Safety And Efficacy ◽

Multicenter Phase ◽

Unresectable Liver Metastases

Download Full-text

Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) after chemotherapy (CT) with CPT-11/L-OHP/LV5FU (Folfirinox): A prospective phase II trial

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.3613 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3613-3613 ◽

Author(s):

F. Quenet ◽

B. Nordlinger ◽

M. Rivoire ◽

J. R. Delpero ◽

G. Portier ◽

...

Keyword(s):

Colorectal Cancer ◽

Liver Metastases ◽

Phase Ii ◽

Phase Ii Trial ◽

Prospective Phase ◽

Unresectable Liver Metastases

Download Full-text

Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial

Annals of Oncology ◽

10.1093/annonc/mdu580 ◽

2015 ◽

Vol 26 (4) ◽

pp. 702-708 ◽

Author(s):

T. Gruenberger ◽

J. Bridgewater ◽

I. Chau ◽

P. García Alfonso ◽

M. Rivoire ◽

...

Keyword(s):

Colorectal Cancer ◽

Liver Metastases ◽

Phase Ii ◽

Phase Ii Trial ◽

Unresectable Liver Metastases

Download Full-text

Faculty Opinions recommendation of A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717697918.793457734 ◽

2012 ◽

Author(s):

Hans-Joachim Schmoll

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

A Randomized Phase II Trial of Pemetrexed plus Irinotecan (ALIRI) versus Leucovorin-Modulated 5-FU plus Irinotecan (FOLFIRI) in First-Line Treatment of Locally Advanced or Metastatic Colorectal Cancer

Oncology ◽

10.1159/000120626 ◽

2007 ◽

Vol 73 (1-2) ◽

pp. 9-20 ◽

Author(s):

Craig Underhill ◽

David Goldstein ◽

Vera A. Gorbounova ◽

Mikhail Y. Biakhov ◽

Igor S. Bazin ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Locally Advanced ◽

Line Treatment ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

Prospective phase II trial of regional hyperthermia and whole liver irradiation for numerous chemorefractory liver metastases from colorectal cancer

Radiation Oncology Journal ◽

10.3857/roj.2016.34.1.34 ◽

2016 ◽

Vol 34 (1) ◽

pp. 34-44 ◽

Author(s):

Jeong Il Yu ◽

Hee Chul Park ◽

Doo Ho Choi ◽

Jae Myoung Noh ◽

Dongryul Oh ◽

...

Keyword(s):

Colorectal Cancer ◽

Liver Metastases ◽

Phase Ii ◽

Phase Ii Trial ◽

Regional Hyperthermia ◽

Prospective Phase

Download Full-text